Showing results (191-200 of 219) with videos related to
Sort By:
Pageof 22
Cancer Letters|September 25, 2024
RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growthSahar F Bannoura, Amro Aboukameel, Husain Yar Khan, et al.Oncogene|June 24, 2021
Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancerJingyuan Wang, Joanne Xiu, Yasmine Baca, et al.JAMA Oncology|January 26, 2023
Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon CancerEn Cheng, Qian Shi, Anthony F Shields, et al.The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.Journal of Surgical Oncology|March 14, 2020
Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinomaMatthew K Stein, Forrest W Williard, Joanne Xiu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic AdenocarcinomaPhilip A Philip, Ibrahim Azar, Joanne Xiu, et al.The Oncologist|August 27, 2024
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT studyErkut H Borazanci, Nathan Bahary, Vincent Chung, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 StudyPhilip A Philip, Vaibhav Sahai, Nathan Bahary, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2020
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Katherine A Guthrie, Van K Morris, et al.Journal of Surgical Oncology|January 11, 2023
Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysisAndrew M Fleming, Benjamin W Deschner, Forrest W Williard, et al.Pageof 22